<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491643</url>
  </required_header>
  <id_info>
    <org_study_id>53211029-02</org_study_id>
    <nct_id>NCT04491643</nct_id>
  </id_info>
  <brief_title>Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma</brief_title>
  <official_title>Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the treatment efficacy of megestrol acetate plus rosuvastatin in patients with&#xD;
      early endometrial carcinoma (EEC) seeking for conservative treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After diagnosed of EEC by hysteroscopy, patients meet the study criteria will be enrolled.&#xD;
      Age, height, weight, waist circumstances, blood pressure, basic history of infertility and&#xD;
      blood pressure will be collected. Blood tests, including fasting blood glucose (FBG), fasting&#xD;
      insulin (FINS), OGTT 2h blood glucose and insulin, blood lipids, SHBG, sex hormone levels,&#xD;
      anti-müllerian hormone(AMH), creatine kinase(CK) and renal/liver function tests will be&#xD;
      performed before treatment to evacuate their basic conditions. Each subject will receive body&#xD;
      fat testing by Inbody 520.&#xD;
&#xD;
      Patients will receive MA (megestrol acetate) 160 mg by mouth daily plus rosuvastatin 10mg by&#xD;
      mouth daily for at least 6 months. Then hysteroscopy will be used to evaluate the endometrial&#xD;
      condition every 3 months, and intra-operative findings will be recorded. Complete response&#xD;
      (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or&#xD;
      secretory endometrium; partial response (PR) is defined as regression to hyperplasia with or&#xD;
      without atypic; stable disease (SD) is defined as the persistence of the disease; and&#xD;
      progressive disease (PD) is defined as the appearance of higher pathological progression, or&#xD;
      myometrial invasion, or extra-uterine metastasis. Continuous therapies will be needed in PR&#xD;
      or NR. Patients with PD will be recommended for hysterectomy.&#xD;
&#xD;
      Due to personal reasons, patients may not accept hysteroscopic evaluation every three months,&#xD;
      then the longest duration will be 8 months. For patients remained SD after 6 to 8 months of&#xD;
      treatment but refused hysterectomy, a multiple disciplinary discussion would be held for&#xD;
      individual case, and alternative treatment would be given.&#xD;
&#xD;
      Two months of maintenance treatment will be recommended for patients with CR, and&#xD;
      participants will be followed up for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Simon two-stage optimal design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>12 to 16 weeks</time_frame>
    <description>From date of initial therapy until the date of CR or date of hysterectomy, whichever come first, assessed up to 16 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>28 to 32 weeks</time_frame>
    <description>From date of initial therapy until the date of CR or date of hysterectomy, whichever come first, assessed up to 32 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response duration</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Pathological response duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate classified by different blood lipid level</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Pathological response rate classified by different blood lipid level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity evaluation</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Toxicity evaluation according to CTCAE 5.0 version.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>Up to 2 years after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>Up to 2 years after the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Endometrial Carcinoma Stage I</condition>
  <arm_group>
    <arm_group_label>MA + Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive MA 160 mg and rosuvastatin 10 mg by mouth daily for at least 6 months. Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.&#xD;
Due to personal reasons, patients may not accept hysteroscopic evaluation every three months, then the longest duration will be 8 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol Acetate</intervention_name>
    <description>At a dosage of 160 mg/day</description>
    <arm_group_label>MA + Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>At a dosage of 10 mg/day</description>
    <arm_group_label>MA + Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a confirmed pathological diagnosis based upon hysteroscopy: histologically prove&#xD;
             well-differentiated EEC G1 without myometrial invasion&#xD;
&#xD;
          -  No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging&#xD;
             (MRI) or enhanced computed tomography (CT) or ultrasound&#xD;
&#xD;
          -  Have a desire for remaining reproductive function or uterus&#xD;
&#xD;
          -  Good compliance with adjunctive treatment and follow-up&#xD;
&#xD;
          -  Abnormal blood lipid. At least meet one of the following five items:&#xD;
&#xD;
               1. Total cholesterol (TC) ≥ 5.2mmol/L (200mg/dL)&#xD;
&#xD;
               2. Low-density lipoprotein cholesterol (LDL-C) ≥ 3.4mmol/L (130mg/dL)&#xD;
&#xD;
               3. Fasting triglycerides (TG) ≥ 1.7mmol/L (150mg/dL)&#xD;
&#xD;
               4. High-density lipoprotein cholesterol (HDL-C) #1.03mmol/L (40mg/dL)&#xD;
&#xD;
               5. Apo-lipoprotein-A (Apo-A) ≥ 1.0g/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute liver disease or liver tumor (benign or malignant) or renal dysfunction&#xD;
&#xD;
          -  Pregnancy or potential pregnancy&#xD;
&#xD;
          -  Under treatment of high-dose progestin therapy more than 1 months in recent 6 months&#xD;
&#xD;
          -  Confirmed diagnosis of any cancer in reproductive system&#xD;
&#xD;
          -  Acute severe disease such as stroke or heart infarction or a history of thrombosis&#xD;
             disease&#xD;
&#xD;
          -  Hypersensitivity or contradiction for using MA or atorvastatin&#xD;
&#xD;
          -  Already diagnosed with hyperlipidemia and using lipid-lowering drugs&#xD;
&#xD;
          -  With other factors of reproductive dysfunction;&#xD;
&#xD;
          -  Strong request for uterine removal or other conservative treatment&#xD;
&#xD;
          -  Smoker (&gt;15 cigarettes a day)&#xD;
&#xD;
          -  Drinker (&gt;20 grams a day)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Chen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrics and Gynecology Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaojun Chen, PhD</last_name>
    <phone>862163455050</phone>
    <email>cxjlhjj@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bingyi Yang, MD</last_name>
    <phone>862163455050</phone>
    <email>xiaomihaoku@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojun Chen</last_name>
      <email>cxjlhjj@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 21, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Obstetrics &amp; Gynecology Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaojun Chen</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>megestrol acetate</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>endometrial carcinoma stage I limited to endometrium</keyword>
  <keyword>conservative treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

